Study evidence-based records on some effective nutraceuticals to be involve in Europe in Major Depression Disorder (MDD) management. Represent nutraceuticals anti-depressant properties to achieve the European health policy targets ‘Investing in Health’ and upkeep sustainable healthcare systems.
Gaining literature by searching MEDLINE (PubMed), Google Scholar, PsychINFO and Quertile databases and retrieving relevant published articles in the peer-reviewed journals.
Results provided evidence of a range of nutraceuticals, which are of potential benefits in management of depression. Studies support the anti-depressant properties of S-Adenosyl Methionine (SAMe), Folnic acid, 5-hydroxytryptophan (5-HTP) and omega-3 fatty acids. The results might give evidence for innovative adjunctive neurobiological line for managing and treating depression in Europe.
Nutraceuticals have specific antidepressant properties that found to be of benefit in psychiatric population and reduce the pharmacotherapeutic side effects.
Randomised controlled trials and evaluation process continue to provide evidence for the nutraceuticals use for depression. Social implications: Nutraceuticals emphasise the Person-focused Medicine, which offers a psychophysical balance to the individual.
Khalifa, N. A., Aljaaly, E. A. (2016): The involvement of nutraceuticals to sustainable heathcare in Europe in the context of major depressive disorder (MDD). In Ahmed, A. (Ed.): Europe at a Crossroads and the Impact of Globalization, Vol. 14, pp. 49-61.
